D'ALESSIO, Andrea
 Distribuzione geografica
Continente #
AS - Asia 210
EU - Europa 179
NA - Nord America 74
SA - Sud America 3
Totale 466
Nazione #
HK - Hong Kong 101
SG - Singapore 98
US - Stati Uniti d'America 71
IT - Italia 51
RU - Federazione Russa 45
DE - Germania 27
AT - Austria 12
IE - Irlanda 12
FI - Finlandia 7
NL - Olanda 7
IN - India 5
UA - Ucraina 5
BR - Brasile 3
CA - Canada 3
CZ - Repubblica Ceca 3
GB - Regno Unito 3
CH - Svizzera 2
BE - Belgio 1
BG - Bulgaria 1
CN - Cina 1
FR - Francia 1
JP - Giappone 1
KR - Corea 1
KZ - Kazakistan 1
LT - Lituania 1
PH - Filippine 1
SE - Svezia 1
UZ - Uzbekistan 1
Totale 466
Città #
Hong Kong 101
Singapore 55
Dublin 12
Moscow 11
Nuremberg 10
Assago 8
Helsinki 7
Vienna 7
Amsterdam 6
Boardman 5
Falkenstein 5
Turin 5
Mezzomerico 4
Milan 4
Novara 4
Santa Clara 4
Los Angeles 3
Pardubice 3
Deiva Marina 2
Florence 2
London 2
Munich 2
New Delhi 2
Toronto 2
Uzzano 2
Valduggia 2
Vercelli 2
Zurich 2
Almaty 1
Ashburn 1
Boca Raton 1
Brussels 1
Cabreúva 1
Delhi 1
Frankfurt am Main 1
Manila 1
Natal 1
Ottawa 1
Paris 1
Seoul 1
Sofia 1
Stockholm 1
Tashkent 1
Trino 1
Uberlândia 1
Totale 291
Nome #
Reply 31
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 27
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 25
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 24
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 24
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 21
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 21
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 19
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 19
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 19
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 18
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 18
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 18
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 17
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 17
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 17
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 17
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 16
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 16
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 16
Reply 15
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 15
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 14
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 14
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 12
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 12
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 12
Totale 494
Categoria #
all - tutte 5.515
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.515


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/2025369 6 2 46 4 5 66 58 41 76 65 0 0
Totale 494